A Randomised, Controlled, Blinded Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian H5 Influenza Vaccine in Adults

Trial Profile

A Randomised, Controlled, Blinded Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian H5 Influenza Vaccine in Adults

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 May 2017

At a glance

  • Drugs ADVAX (Primary) ; Influenza A virus H5N1 vaccines (Primary)
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions
  • Sponsors Vaxine
  • Most Recent Events

    • 15 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 15 Dec 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
    • 08 Dec 2015 Planned End Date changed from 1 Jan 2018 to 1 Dec 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top